Skip to main content
RECCE PHARMACEUTICALS LTD logo

RECCE PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · RCE ISIN · AU000000RCE5 LEI · 549300TKQWXKEHP10T28 ASX Manufacturing
Open in API
Filings indexed 687 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country AU Australia
Listing ASX RCE

About RECCE PHARMACEUTICALS LTD

https://www.recce.com.au

Recce Pharmaceuticals Ltd is dedicated to the development and commercialization of a new class of synthetic anti-infectives designed to address the global challenge of antimicrobial resistance. The company's lead compound, RECCE® 327, is a broad-spectrum synthetic antibiotic engineered with a unique mechanism of action to combat hyper-mutating bacteria, including both Gram-positive and Gram-negative species. This technology is specifically formulated to maintain efficacy over repeated use, targeting critical medical needs such as sepsis, burn wound infections, and urinary tract infections. By utilizing a proprietary synthetic polymer-based platform, the company aims to disrupt bacterial cellular processes in a manner that prevents the development of resistance, providing a potential solution for multi-drug resistant pathogens.

Recent filings

Filing Released Lang Actions
Addendum to Recce Signs Middle East Licensing Term Sheet 2 pages 291.5KB
Regulatory Filings Classification · 78% confidence The document is an ASX announcement providing an addendum to a previously released licensing term sheet announcement. It contains clarification points and compliance statements, and is not an actual financial report, earnings release, management change notice, or other specialized category. It is a general regulatory announcement falling into the fallback category. Therefore, it is classified as Regulatory Filings (RNS).
2026-05-26 English
Recce Signs Middle East Licensing Term Sheet 4 pages 333.4KB
Regulatory Filings Classification · 85% confidence The document is an ASX corporate announcement describing Recce’s entry into a non-binding term sheet for an exclusive licensing agreement. It is not an annual or interim financial report, audit, earnings release, M&A takeover, dividend notice, or capital raise. It provides business update details and approvals for release by the board, fitting the fallback “Regulatory Filings” category for miscellaneous corporate announcements (RNS).
2026-05-26 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 1.0MB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'Quarterly Cash Flow Statement & Operational Highlights' for Recce Pharmaceuticals. It includes detailed quarterly financial data such as cash flows from operating, investing, and financing activities, as well as operational updates including R&D tax rebates, patent grants, clinical trial progress, and collaborations. The presence of a detailed Appendix 4C quarterly cash flow report, which is a regulatory requirement for ASX-listed entities, confirms this is a quarterly financial report. The document contains substantive financial data and analysis for the quarter ended March 2026, not merely an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2026
2026-04-29 English
Positive Regulatory Inspection Outcome for Phase 3 Trial 3 pages 320.5KB
Regulatory Filings Classification · 78% confidence The document is an ASX announcement by Recce Pharmaceuticals regarding the outcome of a routine regulatory inspection of a Phase 3 clinical trial site in Indonesia. It is not an AGM presentation, financial report, earnings release, M&A activity, or any other narrowly defined category. Instead, it is a general regulatory update filed with the exchange, fitting the fallback “Regulatory Filings (RNS)” category.
2026-04-20 English
Notification of cessation of securities - RCE 4 pages 14.9KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of certain securities (options) for RECCE PHARMACEUTICALS LTD. It provides specific information about securities that have ceased, reasons for cessation, and updated issued capital figures. The document is a formal announcement related to changes in the company's securities, specifically the cessation of certain options due to lapse of conditional rights. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about securities changes and does not constitute a full financial report or other specific filing type. The document length is 4260 characters, which is relatively short and consistent with a regulatory announcement rather than a full report.
2026-04-14 English
Brazil Patent Granted for RECCE Anti-Infectives 3 pages 317.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement regarding the granting of a patent in Brazil for Recce Pharmaceuticals' anti-infective products. It details the patent specifics, market information, and company background. There is no financial data, no report attached or referenced as being published, no management or board changes, no earnings or interim report, and no regulatory certification. The content is a formal announcement of a patent grant, which fits best under a general regulatory announcement category rather than a financial or management report. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is under 5,000 characters, and it is a standalone announcement, not a report or presentation.
2026-03-23 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.